Toggle navigation
Home
Search
Services
Blog
Contact
About
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I.
Oscient Pharmaceuticals Corporation, Waltham, MA, United States
Search 27 grants from Jen-I Mao
Search grants from Oscient Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Clustered semi-competing risks analysis in quality of end-of-life care studies
SUMO modification and DNA damage response in cancer therapy
Molecular Basis of Vulnerability to Drug Addiction
Nurse Anesthetist Traineeships
Small Instrumentation Grant
Recently added grants:
Lens epithelial cell heterogeneity during development
Molecular, cellular, anatomical and neurobiological investigation of melanopsin-expressing corneal innervation, and its role in pain and photophobia
Mechanism and Uses of Transmembrane Helix Insertion by Soluble Peptides
New Molecular Probes For Protein Kinases
Molecular characterization of the multi-modal regulation of inositol 1,4,5-trisphosphate receptors
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HG000295-03
Application #
2208690
Study Section
Special Emphasis Panel (ZRG7-SSS-2 (08))
Project Start
1991-02-01
Project End
1996-11-30
Budget Start
1994-12-01
Budget End
1996-11-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Oscient Pharmaceuticals Corporation
Department
Type
DUNS #
City
Waltham
State
MA
Country
United States
Zip Code
02453
Related projects
NIH 1995
R44 HG
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I. / Oscient Pharmaceuticals Corporation
NIH 1994
R44 HG
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I. / Oscient Pharmaceuticals Corporation
Comments
Be the first to comment on this grant